Textile expert Elizabeth Wayland Barber summarizes the historical evidence that Cannabis sativa, "grew and was known in the Neolithic period all across the northern latitudes, from Europe (Germany, Switzerland, Austria, Romania, Ukraine) to East Asia (Tibet and China)," but, "textile use of Cannabis sativa does not surface for certain in the West until relatively late, namely the Iron Age." "I strongly suspect, however, that what catapulted hemp to sudden fame and fortune as a cultigen and caused it to spread rapidly westwards in the first millennium B.C. was the spread of the habit of pot-smoking from somewhere in south-central Asia, where the drug-bearing variety of the plant originally occurred. The linguistic evidence strongly supports this theory, both as to time and direction of spread and as to cause."
Cannabidiol has been found to act as an antagonist of GPR55, a G protein-coupled receptor and putative cannabinoid receptor that is expressed in the caudate nucleus and putamen in the brain. It has also been found to act as an inverse agonist of GPR3, GPR6, and GPR12. Although currently classified as orphan receptors, these receptors are most closely related phylogenetically to the cannabinoid receptors. In addition to orphan receptors, CBD has been shown to act as a serotonin 5-HT1A receptor partial agonist, and this action may be involved in its antidepressant, anxiolytic, and neuroprotective effects. It is an allosteric modulator of the μ- and δ-opioid receptors as well. The pharmacological effects of CBD have additionally been attributed to PPARγ agonism and intracellular calcium release.
In Japan, hemp was historically used as paper and a fiber crop. There is archaeological evidence cannabis was used for clothing and the seeds were eaten in Japan back to the Jōmon period (10,000 to 300 BC). Many Kimono designs portray hemp, or asa (Japanese: 麻), as a beautiful plant. In 1948, marijuana was restricted as a narcotic drug. The ban on marijuana imposed by the United States authorities was alien to Japanese culture, as the drug had never been widely used in Japan before. Though these laws against marijuana are some of the world's strictest, allowing five years imprisonment for possession of the drug, they exempt hemp growers, whose crop is used to make robes for Buddhist monks and loincloths for Sumo wrestlers. Because marijuana use in Japan has doubled in the past decade, these exemptions have recently been called into question.
In September 2018, following its approval by the FDA for rare types of childhood epilepsy, Epidiolex was rescheduled (by the Drug Enforcement Administration) as a Schedule V drug to allow for its prescription use. This change applies only to FDA-approved products containing no more than 0.1 percent THC. This allows GW Pharmaceuticals to sell Epidiolex, but it does not apply broadly and all other CBD-containing products remain Schedule I drugs. Epidiolex still requires rescheduling in some states before it can be prescribed in those states.
Generally speaking, there’s a lot of hype around coconut products that overall aren’t backed by sound science. That’s not to say this oil is going to make you sick, but don’t go overboard. “I am not anti-coconut oil,” says Weinandy. “Our bodies do need some saturated fat. But the industry has done a good job to make it seem like it’s a superfood. The research is definitely not there.”
While normally I'd be slightly tripped up by little things like an overly crowded subway car or a full inbox at work, the CBD oil seems to have taken the edge off of my anxiety a bit. Rather than overthinking a sternly worded email or analyzing a social interaction, I've found it easier to recognize the irrationality of these thoughts and actually let them go (instead of ruminating on the situation). In some ways, I feel more like myself. With that said, I've still experienced some social anxiety when meeting new groups of people—I'd be interested to see what taking the full recommended dose would do.
The wide range of benefits associated with cannabis have garnered interest for use in cancer therapy. Research suggests that cannabinoids, including CBD, may have anti-tumor effects. While this is not enough to define cannabis as a treatment for cancer, it does make it attractive as a complement to other therapies, for both reducing symptoms and possibly enhancing the effects of anticancer drugs.
Prolonged use is not associated with an increased risk of side effects. In research studies, up to 1500 mg of purified CBD per day has been used to address various medical illnesses without reported harmful effects including changes in heart rate, blood pressure, temperature, oxygen and carbon dioxide levels, electrolyte balance, gastrointestinal function, psychomotor functions, or sleep cycles.
My husband was diagnosed with ALS (amyotrophic lateral sclerosis) when he was 61 years old 4 years ago. The Rilutek (riluzole) did very little to help him. The medical team did even less. His decline was rapid and devastating. His arms weakened first, then his hands and legs. Last year, a family friend told us about Rich Herbs Foundation (RHF) and their successful ALS TREATMENT, we visited their website www. richherbsfoundation. com and ordered their ALS/MND Formula, i am happy to report the treatment effectively treated and reversed his Amyotrophic Lateral Sclerosis (ALS), most of the symptoms stopped, he is able to walk and able to ride his treadmill again, he is pretty active now.
LEGAL NOTICES: Care By Design products have not been evaluated by the Food and Drug Administration (FDA). This information is not intended to diagnose, treat or cure any disease. This information should not be interpreted as medical advice or treatment. You should consult your physician or other health care professional before starting any medication or supplements. Further, Care By Design does not manufacture, sell or distribute any products that are in violation of California State Law.
He described an experiment that was done in Brazil in which a 200mg/day dosage of CBD was added to the anticonvulsants epilepsy patients were currently taking. Over the course of several months only 1 of the 7 patients showed no improvement; three became seizure-free; one experienced only one or two seizures, and two experienced reduced severity and occurrence of seizures.